A Phase II Study of Anlotinib(AL3818) in Patients With Advanced Renal Cell Carcinoma(RCC) That Have Failed Or Are Intolerant To TKIs Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs Anlotinib (Primary)
- Indications Carcinoma; Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 27 Dec 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 27 Dec 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 25 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.